UNSPSC 51392401: Arbutamine

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B07L15YAEV. European Medicines Agency schedules Arbutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05555MIG. Arbutamine generally arises in the molecular formula C18H23NO4. The term ARBUTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) Most nations schedule arbutamine under HS 29225000 and SITC 51467.

As of Q4 2014, ARBUTAMINE remains the US FDA Preferred Term for this commodity. Arbutamine bears US NLM identifiers UMLS ID C0172021 and NCI Concept Code C65238. SMILES: OC(CNCCCCC1CCC(O)CC1)C1CC(O)C(O)CC1.

UNSPSC 51392401 Arbutamine, a Commodity code, nominally covers a specific pharmaceutical agent, but recent state and local opportunities tagged under this code show minimal alignment with the code's stated scope. The Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems and the Texas Health and Human Services Commission RFI on Direct-to-Manufacturer Prescriptions represent exploratory pharmaceutical procurement activity, but neither opportunity involves arbutamine procurement or directly mirrors the code's narrow pharmaceutical definition. State and local issuing bodies using this code include county health departments and state health agencies pursuing broader pharmacy benefit programs and emergency-response pharmaceutical supplies. The work being solicited spans naloxone distribution systems for community health initiatives, direct-to-manufacturer prescription fulfillment arrangements, and therapeutic pharmacy programs — activities that sit substantially outside the arbutamine-specific scope the code's name suggests.

Recent activity appears concentrated in Florida and Texas. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, due July 26, 2023 (note: the due date appears inconsistent with the posting date in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for self-insured employer and state agency plans. The code shows little relevant recent activity aligned to arbutamine itself, and the opportunities cited use the code as a nominal pharmaceutical category rather than targeting the specific drug. Prospective vendors should note the mismatch and evaluate whether broader pharmaceutical supply or pharmacy benefit management opportunities are worth pursuing under this code classification.